Ariad ends study of leukemia drug after safety concerns, stock sinks
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals said it’s terminating a study of the company’s drug Iclusig in newly diagnosed leukemia patients due to concerns about blood clots. Shares of the company dropped more than 40%.